1. Home
  2. LOAN vs VERU Comparison

LOAN vs VERU Comparison

Compare LOAN & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.56

Market Cap

50.4M

Sector

Real Estate

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.42

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
VERU
Founded
1989
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.4M
40.9M
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
LOAN
VERU
Price
$4.56
$2.42
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
31.3K
44.5K
Earning Date
04-16-2026
05-07-2026
Dividend Yield
9.48%
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$8,666,307.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$42.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.13
$0.36
52 Week High
$5.85
$4.59

Technical Indicators

Market Signals
Indicator
LOAN
VERU
Relative Strength Index (RSI) 55.34 50.07
Support Level $4.33 $2.13
Resistance Level $4.90 $2.67
Average True Range (ATR) 0.17 0.12
MACD 0.01 0.01
Stochastic Oscillator 43.75 51.16

Price Performance

Historical Comparison
LOAN
VERU

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: